Litigation Details for IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-04-13 |
| Court | District Court, D. Delaware | Date Terminated | 2019-09-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,092,008; 7,691,411; 7,723,390 | ||
| Attorneys | Brian P. Egan | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-08-20 | 107 | Opinion - Memorandum Opinion | of multiple terms in U.S. Patent No. 7,723 ,390 ('" 390 Patent"). (D.I. 70). I have considered… construction for multiple terms in U.S. Patent No. 7,723,390. Within five days the parties shall submit…quot; It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification…compositions for thyroid hormones. ('390 Patent at 1:6-7). The patent descends from an Italian priority application | External link to document |
| 2019-09-10 | 111 | Order | claims of U.S. Patent No. 7,723,390 (" the ' 390 patent") set forth below are…appears in independent claim 1 of the ' 390 patent, and claims 2, 4, 7, 8, and 9 each depend from … claims 1, 2, 4, 7, 8, and 9 of the ' 390 patent are invalid under 35 U.S.C. § 112; and …asserted claims 1, 2, 4, and 7-9 of the ' 390 patent are invalid under 35 U.S.C. § 112; and it is further… 10 September 2019 1:18-cv-00555 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-09-12 | 113 | Order and Final Judgment | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,691,411 B2; 7,723,390 B2. (… 10 September 2019 1:18-cv-00555 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2018-04-13 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,691,411 B2; 7,723,390 B2. (… 10 September 2019 1:18-cv-00555 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-07-11 | 97 | Letter | synonymous with semi-solid. Chyall Tr. at 91:10-92:8. He could not specify the precise relationships…inconsistent with the prosecution history of the ‘390 patent, as according to Dr. Chyall, Plaintiffs’ proposed…substance was a half-liquid according to the ’390 patent. Id. at 50:7-14; 74:21-75:11. B. Deposition…to persons of skill in the art pertinent to the patent in suit: “My opinion is that half-liquid term –… at the time of the application for the ’390 patent would not have been able to discern with reasonable | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
